Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
This article was originally published in The Pink Sheet Daily
Executive Summary
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.